all

I am honored to be chosen to keep this chair warm for the next year, and excited about the opportunity to serve the NLA, and all the members of the Southwest Chapter.   I am grateful to have received this position after it has been in the excellent care of my predecessor, Judy Collins.  I hope to move forward  with the ideas and hard work she has instituted during her tenure.  I also hope to see our chapter grow, involving ever more members as we collectively spread the word about the NLA, and continue to encourage as many as possible to become certified.  I want to do my part to help the a

An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.

The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.

Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.

Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.

Among the results presented today: